5 -bromo-2-(p-tolyl)pyrimidine | 1192164-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5 -bromo-2-(p-tolyl)pyrimidine
• 英文别名: 5-bromo-2-(4-methylphenyl)pyrimidine
• CAS: 1192164-49-0
• 化学式: C₁₁H₉BrN₂
• 分子量: 249.11
• InChiKey: HQTGUHQQKJJYMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5 -bromo-2-(p-tolyl)pyrimidine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 碳酸氢钠 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.5h， 生成 tert-butyl N-(5-aminopyrazine-2-carbonyl)-N-(4-(5-(4’-ethyl-[1,1’-bi(cyclohexan)]-3-en-4-yl)pyrimidin-2-yl)benzyl)glycinate
  参考文献：
  名称：

  [EN] NOVEL GLP-1 RECEPTOR MODULATORS
  [FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR DU GLP-1

  摘要：

  提供了调节胰高血糖素样肽1（GLP-1）受体的化合物，以及含有这些化合物的产品，以及它们的使用和合成方法。这些化合物具有如下的结构式（I）或其药用盐，其中A、J、W1、Y、Z、R1、R2、R3和R4的定义如下。

  公开号：

  WO2018200833A1
• 作为产物：
  描述：

  4-甲苯硼酸 、 5-溴-2-碘嘧啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 16.0h， 以58%的产率得到5 -bromo-2-(p-tolyl)pyrimidine
  参考文献：
  名称：

  [EN] NOVEL GLP-1 RECEPTOR MODULATORS
  [FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR DU GLP-1

  摘要：

  提供了调节胰高血糖素样肽1（GLP-1）受体的化合物，以及含有这些化合物的产品，以及它们的使用和合成方法。这些化合物具有如下的结构式（I）或其药用盐，其中A、J、W1、Y、Z、R1、R2、R3和R4的定义如下。

  公开号：

  WO2018200833A1

文献信息

• 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND
  申请人：Kuribayashi Takeshi

  公开号：US20110112103A1

  公开（公告）日：2011-05-12

  The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R 1 represents a group —X-Q 1 , X-Q 1 -Y-Q 2 or X-Q 1 -Y-Q 2 -Z-Q 3 , X represents a single bond, —CH 2 — or the like, Q 1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH 2 —, or the like, Q 2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR 11 R 12 — or the like, R 11 and R 12 each independently represents a hydrogen atom, a halogen atom or the like, Q 3 represents a phenyl group which may have substituent(s), a C 3 -C 7 cycloalkyl group which may have substituent(s), a C 3 -C 7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R 2 represents a C 1 -C 3 alkyl group or the like, and R 3 represents a hydrogen atom or a methyl group].

  本发明提供促进促红细胞生成素产生的化合物。提供以下一般式（1）表示的化合物或其药理学上可接受的盐： [其中，R 1 表示一个基团-X-Q 1 ，X-Q 1 -Y-Q 2 或X-Q 1 -Y-Q 2 -Z-Q 3 ，X表示一个单键，-CH 2 -或类似物，Q 1 表示可能具有取代基的单环或双环杂环基团，Y表示一个单键，-CH 2 -或类似物，Q 2 表示可能具有取代基的单环或双环碳氢环基团或可能具有取代基的单环或双环杂环基团，Z表示一个单键，-CR 11 R 12 -或类似物，R 11 和R 12 各自独立地表示氢原子、卤素原子或类似物，Q 3 表示可能具有取代基的苯基团，可能具有取代基的C 3 -C 7 环烷基团，可能具有取代基的C 3 -C 7 环烯基团或可能具有取代基的单环或双环杂环基团，R 2 表示C 1 -C 3 烷基团或类似物，R 3 表示氢原子或甲基基团]。
• Novel compounds that are ERK inhibitors
  申请人：Deng Yongqi

  公开号：US20070232610A1

  公开（公告）日：2007-10-04

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及一种化学式1.0的ERK抑制剂，以及其药学上可接受的盐和溶剂。其中，Q为一个哌啶或哌嗪环，可以有一个桥或一个融合环。哌啶环中可以在环中有一个双键。所有其他取代基如定义所述。本发明还涉及使用化合物1.0治疗癌症的方法。
• GLP-1 receptor modulators
  申请人：RECEPTOS LLC

  公开号：US11530205B2

  公开（公告）日：2022-12-20

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as products containing such compounds, and methods of their use and synthesis. Such compounds have the structure of Formula (I) below: (I) or pharmaceutically acceptable salts thereof, wherein A, J, W 1 , Y, Z, R 1 , R 2 , R 3 and R 4 are as defined herein.

  本文提供了调节胰高血糖素样肽 1（GLP-1）受体的化合物、含有此类化合物的产品及其使用和合成方法。此类化合物具有下式 (I) 结构：(I) 或其药学上可接受的盐，其中 A、J、W 1 ，Y，Z，R 1 , R 2 , R 3 和 R 4 如本文所定义。
• LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME
  申请人：Tanaka Kenta

  公开号：US20110177312A1

  公开（公告）日：2011-07-21

  A laminated structure comprising an electrode, a polymer binding layer arranged on the electrode, and an electrically conductive organic material layer arranged on the polymer binding layer, wherein the polymer binding layer comprises an aromatic polymeric compound which has a structure represented by formula (I) [wherein Ar represents a conjugated divalent group which may have a substituent, provided that when there are multiple Ar's, the Ar's may be the same as or different from each other; and n represents an integer of 1 or greater] and has a number average molecular weight of 1×10 3 to 1×10 8 inclusive in terms of polystyrene content, the polymer binding layer is bonded to the electrode via a chemical bond between the aromatic polymeric compound and the surface of the electrode, and an electrically conductive organic material that composes a layer included in the electrically conductive organic material layer and arranged adjacent to the polymer binding layer has a number average molecular weight of 3×10 2 to 1×10 8 inclusive in terms of polystyrene content.
• PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AND USE THEREOF
  申请人：GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES

  公开号：US20170313697A1

  公开（公告）日：2017-11-02

  Disclosed in the disclosure are a pyrazolo[1,5-a]pyrideine compound with structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 μg/mL and partially achieves 0.01 μg/mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a]pyrideine compounds of the present disclosure can effectively scavenge the infectious dose of H37Ra in a mouse body at 20 mg/kg/d does, thereby being a new type of antituberculosis compound.